USFDA issues 'Form 483' with three observations to Lupin US facility
New Delhi, April 18 (IANS) Major drug maker Lupin on Saturday said that the US health regulator has issued a 'Form 483' with three observations to its manufacturing facility in Somerset, New Jersey, following a recent inspection.